CompletedNCT00325689

Aripiprazole added to antipsychotic treatment for schizophrenia

About this title

Medication studyAges 18+United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations: Little Rock and 47 more locationsSee all locations and recruitment
Study phase: Phase 4

Study clarity

Study start dateJuly 2006

Recruitment status: Completed
Enrollment listed in the registry: 323
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: United States
Age range: Over 18 Years
Official registry ID: NCT00325689
Official title: Show the full official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy.

Completed

Little Rock · Cerritos · Costa Mesa

37 more locations

FAQ

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine or Risperidone + Aripiprazole and Quetiapine or Risperidone + placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.